The impact of intravesical prostate protrusion on the treatment outcomes in patients with benign prostatic hyperplasia
https://doi.org/10.21886/2308-6424-2025-13-5-80-85
Abstract
Introduction. Benign prostatic hyperplasia (BPH) is the most common cause of bladder outlet obstruction in men over 50 years old who have lower urinary tract symptoms.
Objective. To investigate the impact of intravesical prostate protrusion (IPP) during sonography concerning the response to medical treatment in patients with BPH.
Materials & methods. This study is a descriptive-analytical quasi-experimental. The individuals (80 patients) were divided into two groups based on the presence or absence of IPP as seen in ultrasound. Before and after one month of treatment with the alpha-blocker, PVR and IPSS were measured in the patients, and the improvement trends in the two groups were compared.
Results. The mean age of patients in both groups was 66.08 ± 10.8 years. After treatment with alpha-blockers, the mean PVR in IPP-patients was 6.82 ± 5.6 ml, and in no-IPP-patients it was 25.37 ± 15.57 ml (P > 0.001). After treatment with alpha-blockers, the mean score in IPP-patients was 6.78 ± 9.52, and in no-IPP-patients it was 12.55± 6.99 (P = 0.388).
Conclusion. The results indicate that the effect of the alpha-blocker medication on patients with IPP was greater than on those without IPP, highlighting the positive impact of using alpha-blockers in patients with BPH who have IPP.
About the Authors
R. Shahraini
Sabzevar University of Medical Sciences
Islamic Republic of Iran
Islamic Republic of Iran
Ramin Shahraini — Assist. Prof.
Sabzevar
R. AghaBarati
Sabzevar University of Medical Sciences
Islamic Republic of Iran
Islamic Republic of Iran
Reyhaneh AghaBarati
Sabzevar
Ya. Tabarraie
Sabzevar University of Medical Sciences
Islamic Republic of Iran
Islamic Republic of Iran
Yaser Tabarraie — Ph.D., Assist. Prof.
Sabzevar
Z. Jalambadani
Sabzevar University of Medical Sciences
Islamic Republic of Iran
Islamic Republic of Iran
Zeinab Jalambadani — Ph.D., Assist. Prof.
Sabzevar
M. Mehrmanesh
Islamic Azad University (IAU)
Islamic Republic of Iran
Islamic Republic of Iran
Maliheh Mehrmanesh — M.Sc. in Midwifery
Tehran
References
1. Kalkanli A, Tandogdu Z, Aydin M, Karaca AS, Hazar AI, Balci MB, Aydin M, Nuhoglu B. Intravesical Prostatic Protrusion: A Potential Marker of Alpha-blocker Treatment Success in Patients With Benign Prostatic Enlargement. Urology. 2016;88:161-5. DOI: 10.1016/j.urology.2015.11.029
2. Sandhu JS, Bixler BR, Dahm P, Goueli R, Kirkby E, Stoffel JT, Wilt TJ. Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia (BPH): AUA Guideline Amendment 2023. J Urol. 2024;211(1):11-19. DOI: 10.1097/JU.0000000000003698
3. Wei H, Zhu C, Huang Q, Yang J, Li YT, Zhang YG, Li BH, Zi H. Global, regional, and national burden of benign prostatic hyperplasia from 1990 to 2021 and projection to 2035. BMC Urol. 2025;25(1):34. DOI: 10.1186/s12894-025-01715-9
4. Wolfe RC, Portell J, Maamari JA. Pharmacologic Management of Postoperative Urinary Retention. J Perianesth Nurs. 2023;38(4):667-670. DOI: 10.1016/j.jopan.2023.05.006
5. Britto-Júnior J, Guimarães RAB, Oliveira DL, Lima AT, Quirino Junior G, de Oliveira Stocco GA, Salgado Uramoto EH, Fregonesi A, Antunes E, De Nucci G. Alpha1-adrenergic blockers selectively antagonize the contractions induced by 6-nitrodopamine in the human vas deferens. Naunyn Schmiedebergs Arch Pharmacol. 2024;397(5):3227-3238. DOI: 10.1007/s00210-023-02805-x
6. Sciacqua LV, Vanzulli A, Di Meo R, Pellegrino G, Lavorato R, Vitale G, Carrafiello G. Minimally Invasive Treatment in Benign Prostatic Hyperplasia (BPH). Technol Cancer Res Treat. 2023;22:15330338231155000. DOI: 10.1177/15330338231155000
7. Chughtai B, Rojanasarot S, Neeser K, Gultyaev D, Fu S, Bhattacharyya SK, El-Arabi AM, Cutone BJ, McVary KT. A comprehensive analysis of clinical, quality of life, and cost-effectiveness outcomes of key treatment options for benign prostatic hyperplasia. PLoS One. 2022;17(4):e0266824. DOI: 10.1371/journal.pone.0266824
8. Eze BU, Amu OC, Edeh JA. A Review of Intravesical Prostatic Protrusion in the Evaluation and Treatment of Benign Prostatic Enlargement. European Journal of Medical and Health Sciences. 2021;3(1):13-17.
9. Suastari NMP, Mahayani NMW, Dinata DKAHP. Correlation between Prostate Volume and Intravesical Prostate Protrusion to Bladder Detrusor Muscle Thickness in Patients with Benign Prostate Enlargement by Transabdominal Ultrasound Examination in Banjar Jagatamu, Meliling, Kerambitan, Tabanan 2024. Al Makki Health Informatics Journal. 2025;3(1):37-43.
10. Chen X, Yang S, He Z, Chen Z, Tang X, Lin Y, Huang Y, Hou J, Wei X. Comprehensive analysis of the global, regional, and national burden of benign prostatic hyperplasia from 1990 to 2021. Sci Rep. 2025;15(1):5644. DOI: 10.1038/s41598-025-90229-3
11. Raffo M, Capogrosso P, Pozzi E, Belladelli F, Corsini C, Bertini A, Negri F, Candela L, Larcher A, Matloob R, d’Arma A, Montorsi F, Salonia A. Clinical predictors of bladder outlet obstruction in men consulting for routine urological screening. Int Urol Nephrol. 2025;57(8):2513-2518. DOI: 10.1007/s11255-025-04432-2
12. Creta M, Baboudjian M, Sakalis V, Bhatt N, Nunzio C, Gacci M, Herrmann TRW, Karavitakis M, Malde S, Moris L, Netsch C, Rieken M, Schouten N, Tutolo M, Yuan Y, Hashim H, Cornu JN. Management of Primary Bladder Neck Obstruction and Dysfunctional Voiding in Young Men: A Systematic Review and Meta-analysis. Eur Urol Focus. 2025;11(3):496-507. DOI: 10.1016/j.euf.2025.01.011
13. Cumpanas AA, Botoca M, Minciu R, Bucuras V. Intravesical prostatic protrusion can be a predicting factor for the treatment outcome in patients with lower urinary tract symptoms due to benign prostatic obstruction treated with tamsulosin. Urology. 2013;81(4):859-863. DOI: 10.1016/j.urology.2012.12.007
14. Yoshida T, Kinoshita H, Yoshida K, Mishima T, Taniguchi H, Yanishi M, Komai Y, Yasuda K, Sugi M, Matsuda T. Intravesical Prostatic Protrusion as a Predicting Factor for the Adverse Clinical Outcome in Patients With Symptomatic Benign Prostatic Enlargement Treated With Dutasteride. Urology. 2016;91:154-157. DOI: 10.1016/j.urology.2016.01.009
15. Lee HJ, Lee A, Huang HH, Sundaram P, Foo KT. Patients with small prostates and low-grade intravesical prostatic protrusion – A urodynamic evaluation. Asian J Urol. 2017;4(4):247-252. DOI: 10.1016/j.ajur.2017.03.003
Review
For citations:
Shahraini R., AghaBarati R., Tabarraie Ya., Jalambadani Z., Mehrmanesh M. The impact of intravesical prostate protrusion on the treatment outcomes in patients with benign prostatic hyperplasia. Urology Herald. 2025;13(5):80-85. https://doi.org/10.21886/2308-6424-2025-13-5-80-85
Views:
15
Email this article 